Study Evaluating Effexor XR in Elderly Patients With Major Depression.

Phase 3CompletedNCT00225485

Wyeth is now a wholly owned subsidiary of Pfizer100 enrolled

Overview

Phase III study evaluating Effexor XR in elderly patients with major depression.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

100

Conditions

Depression

Interventions

Effexor XRDRUG

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with major depression based on DSM-IV-TR * Patients having minimal total score of 18 on the HAM-D17 and minimal score of 2 on the item of "depressed mood" of HAM-D at baseline Exclusion Criteria: * Patients with schizophrenia or any other psychotic disorder * Patients with history or presence of bipolar disorder

Locations (37)

Unnamed facility

Ichikawa, Chiba, Japan

Outcomes

Primary Outcomes

Response rate of HAM-D17 (Hamilton Rating Scale for Depression) at the final-on-therapy

Secondary Outcomes

Difference of total score of HAM-D17 between baseline and final-on-therapy

Remission rate of HAM-D17 at the final-on-therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.